A self-petition green card for Australian professionals whose record already speaks for itself — no US employer, no PERM labor certification. Tech executives at Atlassian or Canva, CSIRO researchers, and CSL or Cochlear scientists often hold the kind of documented record — contributions adopted at scale, publications, patents, and institutional prestige — that satisfies USCIS's extraordinary ability standard. No country-cap wait for Australian nationals.
A green card built on Australian professional and research credentials.
Australia produces EB-1A petitioners across a concentrated set of high-achieving sectors. Sydney is home to Atlassian — one of the world's most valuable enterprise software companies — and Canva, plus a growing cohort of well-funded startups, generating founders and executives with documented records of original contribution, critical role, and press coverage in internationally recognized outlets. Melbourne anchors a biomedical research cluster around CSL Limited, one of the world's largest biotech companies by market cap, and Cochlear, the global leader in cochlear implant technology — together generating scientists and engineers with deep patent portfolios and clinical-development records.
CSIRO, Australia's national science agency, and the Group of Eight research universities — ANU, University of Melbourne, University of Sydney, UNSW, and four others — produce researchers with records comparable to those from the most recognized European research institutions. Because EB-1A requires no job offer and no labor certification, Australian professionals in any of these sectors can self-petition directly, then file the same evidence for an O-1A nonimmigrant petition while the green card is pending. There is no country-cap wait for Australian nationals.
Atlassian & Sydney tech
Home to Atlassian (Jira, Confluence, Trello), Canva, Afterpay, and a growing startup cohort; tech executives build EB-1A records through critical role at a globally recognized company, original contributions (products adopted at scale), and press coverage in international tech outlets.
CSIRO
Australia's national science agency, internationally recognized across agriculture, climate, materials, health, and data science; senior researchers satisfy original contributions, scholarly articles, judging through ARC panels, and critical role through principal scientist or program leader positions.
CSL Limited
Melbourne-headquartered global biotech company; scientists qualify through original contributions (drug candidates and plasma fractionation methods documented with patents), scholarly articles, judging through peer review, and critical role at the principal scientist or director level.
Cochlear
Sydney-headquartered global leader in cochlear implant technology; engineers and researchers hold deep patent portfolios in biomedical engineering and audiology that commonly satisfy original contributions, articles, and critical role criteria.
Go8 university researchers
ANU, University of Melbourne, UNSW, University of Sydney, Monash, UQ, UWA, and Adelaide are all internationally ranked research universities; faculty and senior researchers satisfy EB-1A criteria comparable to those from equivalent European institutions.
No country-cap wait
Australian nationals face no meaningful visa bulletin backlog under EB-1A. An approved I-140 can proceed quickly to adjustment of status or consular processing — a significant advantage over employer-sponsored PERM-based categories.
Eligibility criteria
The EB-1A criteria for Australian professionals.
Three of ten criteria must be satisfied, followed by a final merits determination. For Australian professionals, tech cases lean on original contributions, press, and critical role; research cases lean on contributions, articles, and judging; biomedical cases lean on contributions, articles, and critical role.
01 — PRIZES
Awards & prizes
ARC prizes, Prime Minister's Prize for Science, ARC Laureate Fellowship selection, AIIA industry awards, biomedical engineering recognitions, CSL and Cochlear internal research excellence awards.
02 — MEMBERSHIP
Exclusive membership
Australian Academy of Science fellowship; ATSE fellowship; editorial board service on international peer-reviewed journals; professional memberships requiring outstanding achievement.
03 — PRESS
Published material about the person
Australian Financial Review and The Australian for business and tech; TechCrunch, Wired, and Bloomberg for startups; Nature News and STAT News for biomedical coverage.
04 — JUDGING
Judging others' work
ARC and NHMRC grant review panels; peer review for Nature, Cell, or leading engineering journals; conference program committee service at top international venues.
05 — CONTRIBUTIONS
Original contributions of major significance
A startup product adopted at scale; a CSIRO research method adopted across the field; a Cochlear engineering innovation incorporated into production; a CSL drug candidate advanced through clinical development.
06 — ARTICLES
Scholarly articles
Publications in Nature, Science, Cell, The Lancet, or field-leading journals; IEEE Transactions for engineers; audiology and biomedical engineering journals for Cochlear and CSL researchers.
07 — CRITICAL ROLE
Critical or essential role
C-level or VP at Atlassian, Canva, or a recognized Australian startup; CSIRO research program leader or principal scientist; principal scientist or director at CSL or Cochlear.
08 — HIGH SALARY
High salary
Senior Australian tech and biomedical compensation, benchmarked against equivalent US occupational pay bands.
Australian EB-1A profiles
What qualifying records look like here.
Representative profiles from Australian EB-1A petitions. Identifying details have been generalized.
CTO & Co-Founder
Series C SaaS company — Sydney
AI-powered contract intelligence platform for enterprise legal teams
Platform used by legal teams at 400+ Fortune 1000 companies; 2 patents on clause extraction methods
Profiled in TechCrunch, Australian Financial Review, and Harvard Business Review
Invited to testify as an expert at an Australian parliamentary committee on AI in legal practice
Compensation in the 94th percentile per Australian startup executive survey data
Criteria satisfied: contributions (platform scale and patent adoption, documented with usage data and expert letters from legal tech faculty), press (TechCrunch, AFR, HBR), critical role (CTO/co-founder of a recognized company), high salary.
Senior Principal Research Scientist
CSIRO — Health and Biosecurity
Rapid diagnostic platform for emerging viral pathogens
23 publications; senior-author papers in Nature Communications and The Lancet Infectious Diseases
2,700+ citations; diagnostic platform licensed to 2 US diagnostic companies
ARC Laureate Fellowship; peer reviewer for The Lancet and PLOS Medicine
WHO technical advisory panel service; collaboration with CDC and NIH on outbreak response protocols
Criteria satisfied: articles (Nature Communications, The Lancet Infectious Diseases), contributions (diagnostic platform licensing and citation record), judging (The Lancet peer review, ARC grant panel), critical role (senior principal research scientist and ARC Laureate Fellow at Australia's national science agency).
Principal Engineer, Implant Electronics
Leading hearing implant company — Sydney
Low-power neural stimulation ASICs for cochlear implant sound processors
12 granted patents; ASIC architecture incorporated in two commercial implant generations
4 publications in IEEE Transactions on Biomedical Circuits and Systems
Compensation at 91st percentile per Australian biomedical engineering survey data
Expert letters from 4 US-based biomedical engineering faculty at MIT and Johns Hopkins
Criteria satisfied: contributions (patents and commercial incorporation, corroborated by expert letters from biomedical faculty), articles (IEEE Transactions), high salary, critical role (principal engineer on a commercial program at the global market leader).
From E-3 to EB-1A
The Australian path to permanent residence.
The most common trajectory for accomplished Australian professionals is: E-3 for initial US work authorization → build the extraordinary ability record over 2–5 years → self-petition for EB-1A when the record meets the standard. Because there is no country-cap wait for Australian nationals, an approved I-140 proceeds quickly to a green card through adjustment of status or consular processing — without the multi-year PERM labor certification timelines that employer-sponsored EB-2 and EB-3 categories require.
Australia's lack of an E-2 treaty means there is no capital-driven nonimmigrant fallback for founders and investors — for Australian-born founders with an extraordinary ability record, EB-1A is the primary self-directed route to permanent residence. EB-1A and O-1A use overlapping evidence and can be built in parallel.
Treaty status
Australia does not have an E-2 Treaty Investor agreement with the United States, and does not have a country-cap backlog under EB-1A. For Australian professionals whose record demonstrates extraordinary ability, EB-1A is the most direct self-petition route to a US green card — without an employer, without PERM, and without a wait.
FAQ
Australia EB-1A questions.
Yes. EB-1A is a self-petition category — no US employer, job offer, or PERM labor certification is required. Australian nationals in tech, research, or biomedical fields file the I-140 directly with USCIS. There is no country-cap wait for Australian nationals under EB-1A.
Australians frequently begin on E-3, build their professional record over 2–5 years, and self-petition for EB-1A when their record reaches the extraordinary ability standard. EB-1A can be filed while E-3 is in place, and once approved, can proceed quickly to a green card — there is no country-cap wait for Australian nationals.
Yes. Australian tech executives build EB-1A records through critical role at a globally recognized company, original contributions (products adopted at scale), and press coverage in international outlets. High salary, benchmarked against US comparable roles, is commonly a fourth criterion.
Yes. CSIRO senior researchers regularly satisfy multiple EB-1A criteria: original contributions (methods adopted across the field), scholarly articles in leading journals, judging through ARC grant panels and peer review, and critical role through principal scientist or program leader appointments.
No. Australian nationals face no meaningful visa bulletin backlog under EB-1A. An approved I-140 can proceed quickly to adjustment of status or consular processing — a significant advantage over employer-sponsored PERM-based categories.
